Huakang Biomed (08622.HK) announced that the Group intends to carry out enzyme-based product trading business involving the online sales platform and the enterprise-to-enterprise operation Enzyme Good Life Group (China) Limited ("New Business Activities").
As of the announcement date, the Group is mainly engaged in the research and development, production, marketing and sales of in vitro diagnostic reagents and assisted reproductive products and equipment in China. The Board of Directors is actively exploring new business opportunities to bring higher returns to shareholders. Considering the sustained growth potential of the enzyme-based product and e-commerce industry consumption in China in recent years, the Board believes that the development of new business activities will provide an opportunity for the Group to diversify its sources of income and ultimately improve its financial performance. The Board of Directors believes that the development of new business activities will be in the overall interests of the company and shareholders.